The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
Open accessAbstract
This minireview touches upon the challenges and opportunities peptides experience on the track to become an approved pharmaceutical. Peptide attributes originally considered troublesome with respect to drug development may now turn out to be more convenient rather than unfavourable. Besides characteristic high target affinity, biological peptides often exhibit higher than expected stability. Clearly natural selective pressure has optimised these biomolecules beyond what can be anticipated solely on the basis of their chemical nature. This concept is gradually finding its way into the pharma and biotech industry, as illustrated by a rise in medicinal peptide patent applications and developmental work.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies
Hancock, R. E. W., & Sahl, H.-G. (2006) · Nature Biotechnology · doi:10.1038/nbt1267 · Cited by 4,208
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
Expanding the Genetic Code of Escherichia coli
Wang, L., Brock, A., Herberich, B., & Schultz, P. G. (2001) · Science · doi:10.1126/science.1060077 · Cited by 1,499
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Diversity of antimicrobial peptides and their mechanisms of action
Epand, R. M., & Vogel, H. J. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00198-4 · Cited by 1,358
Houghten, R. A., Pinilla, C., Blondelle, S. E., Appel, J. R., Dooley, C. T., & Cuervo, J. H. (1991) · Nature · doi:10.1038/354084a0 · Cited by 1,326
McDonnell, L. A., & Heeren, R. M. A. (2007) · Mass Spectrometry Reviews · doi:10.1002/mas.20124 · Cited by 1,082
Emerging roles of proteases in tumour suppression
López-Otín, C., & Matrisian, L. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2228 · Cited by 802
Therapeutic potential of venom peptides
Lewis, R. J., & Garcia, M. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1197 · Cited by 798
Cited by
Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller-Salvia, B., Sánchez-Navarro, M., Giralt, E., & Teixidó, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 442
Eskandari, S., Guerin, T., Toth, I., & Stephenson, R. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.013 · Cited by 381
Mechanisms of Action for Antimicrobial Peptides With Antibacterial and Antibiofilm Functions
Raheem, N., & Straus, S. K. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02866 · Cited by 369
Late‐Stage Peptide Diversification by Position‐Selective C−H Activation
Wang, W., Lorion, M. M., Shah, J., Kapdi, A. R., & Ackermann, L. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201806250 · Cited by 335
Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics
Erak, M., Bellmann-Sickert, K., Els-Heindl, S., & Beck-Sickinger, A. G. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.012 · Cited by 324
Rapid and efficient protein synthesis through expansion of the native chemical ligation concept
Kulkarni, S. S., Sayers, J., Premdjee, B., & Payne, R. J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0122 · Cited by 323
Böttger, R., Hoffmann, R., & Knappe, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178943 · Cited by 307
Aguirre, T. A. S., Teijeiro-Osorio, D., Rosa, M., Coulter, I. S., Alonso, M. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.004 · Cited by 299
Admassu, H., Gasmalla, M. A. A., Yang, R., & Zhao, W. (2018) · Journal of Food Science · doi:10.1111/1750-3841.14011 · Cited by 293
de Castro, R. J. S., & Sato, H. H. (2015) · Food Research International · doi:10.1016/j.foodres.2015.05.013 · Cited by 280
Peptidomimetic therapeutics: scientific approaches and opportunities
Qvit, N., Rubin, S. J. S., Urban, T. J., Mochly-Rosen, D., & Gross, E. R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.003 · Cited by 273
Nanotechnology Formulations for Antibacterial Free Fatty Acids and Monoglycerides
Jackman, J., Yoon, B., Li, D., & Cho, N.-J. (2016) · Molecules · doi:10.3390/molecules21030305 · Cited by 109
Meneguetti, B. T., Machado, L. D. S., Oshiro, K. G. N., Nogueira, M. L., Carvalho, C. M. E., & Franco, O. L. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02136 · Cited by 77
Bridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
Sabatino, G., D’Ercole, A., Pacini, L., Zini, M., Ribecai, A., Paio, A., Rovero, P., & Papini, A. M. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00490 · Cited by 21
HighMPNN: A Graph Neural Network Approach for Structure-Constrained Cyclic Peptide Sequence Design
Xu, W., Zhang, C., Shang, T., Mao, Q., Guo, J., & Duan, H. (2026) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3620163 · Cited by 8
Metadata
- Authors
- Uhlig, T., Kyprianou, T., Martinelli, F. G., Oppici, C. A., Heiligers, D., Hills, D., Calvo, X. R., & Verhaert, P.
- Venue
- EuPA Open Proteomics
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 4
- Pages
- 58-69
- ISSN
- 2212-9685 (ISSN-L)
- OpenAlex
- W2034265369
- Cited by
- 456
- References
- 43
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.